The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, shares thoughts on whether anti-BCMA CAR-T cell therapy looks promising as a treatment option for multiple myeloma (MM) patients
Published: 14 December 2018
Jasmine Zain, MD, on the most exciting studies in lymphoma presented at ASH 2018
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, ...
Yana Pikman, MD, regarding research outcomes from the LEAP Consortium
Dr. Pikman, Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Children’s Hospital, explains how the results of the LEAP Consortium’s ...
Jasmine Zain, MD, discusses novel treatment research regarding transplants at City of Hope
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses ...
Jasmine Zain, MD, considers the impact of the new induction regimen in PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, ...
Yana Pikman, MD, on the efforts of the LEAP Consortium in pediatric acute leukemia
Dr. Pikman, Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Children’s Hospital, explains the LEAP Consortium and how the group ...
Jasmine Zain, MD, defines successful induction regimens when treating PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses ...
Jasmine Zain, MD, elaborates on the investigation of novel induction regimens in PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, tells ...
Jasmine Zain, MD, regarding the standard of care in treatment of PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, explains ...
Carol Moreno, MD, PhD, discusses MRD as a legitimate surrogate marker in CLL
Dr. Moreno, Hematologist, University of Barcelona, considers whether minimal residual disease (MRD) is a legitimate surrogate marker for response and ...
Carol Moreno, MD, PhD, describes recent advancements in the treatment of CLL
Dr. Moreno, Hematologist, University of Barcelona, elaborates on recent advancements in the treatment of chronic lymphocytic leukemia (CLL)
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
